| Polo样激酶1抑制剂临床前和早期临床研究进展 |
| |
| 引用本文： | 孙天宇,孙建国,王广基.Polo样激酶1抑制剂临床前和早期临床研究进展[J].药学与临床研究,2011,19(2):146-150. |
| |
| 作者姓名： | 孙天宇 孙建国 王广基 |
| |
| 作者单位： | 中国药科大学药代重点实验室,南京,210009 |
| |
| 摘 要： | Polo样激酶1(PLK 1)是一种高度保守的丝氨酸/苏氨酸蛋白激酶,在细胞有丝分裂过程中发挥重要作用。人类80%的肿瘤类型中,PLK1高度表达。PLK1的过表达与部分肿瘤的预后不良和整体存活率较低相关。PLK1抑制剂对有丝分裂的不同阶段具有干扰作用,如中心体的成熟、纺锤体的形成、染色体的分离和胞质分裂等,最终导致肿瘤细胞凋亡。综述PLK1抑制剂临床前和早期临床的研究进展。
|
| 关 键 词： | Polo样激酶1 有丝分裂 Polo样激酶1抑制剂 肿瘤 |
| 收稿时间： | 2010/12/24 0:00:00 |
| 修稿时间： | 2011/1/18 0:00:00 |
Preclinical Research and Early Clinical Research of Polo-like Kinase 1 Inhibitors |
| |
| SUN Tian-yu,SUN Jian-guo and WANG Guang-ji.Preclinical Research and Early Clinical Research of Polo-like Kinase 1 Inhibitors[J].Pharmacertical and Clinical Research,2011,19(2):146-150. |
| |
| Authors: | SUN Tian-yu SUN Jian-guo and WANG Guang-ji |
| |
| Affiliation: | SUN Tian-yu,SUN Jian-guo,WANG Guang-ji Laboratory of Pharmacokinetics,China Pharmaceutical University,Nanjing 210009,China |
| |
| Abstract: | Polo-like kinase 1(PLK1) is a highly conserved serine/threonine protein kinases that plays a key role in regulation of mitosis.In about 80% of human tumors,of various origins,PLK1 is over expressed.Over-expression of PLK1 is associated with a poor prognosis in several tumor types and a lower overall survival rate.PLK1 inhibitor can interfere with different stages of mitosis,such as centrosome maturation,spindle formation,chromosome separation,and cytokinesis.This review includes an overview of PLK1 inhibito... |
| |
| Keywords: | Polo-like kinase Mitosis Polo-like kinase 1 inhibitor Tumor |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《药学与临床研究》浏览原始摘要信息 |
|
点击此处可从《药学与临床研究》下载全文 |
|
